Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: An open-label study in healthy white subjects in germany

Clinical Therapeutics

Volumn 36, Issue 5, 2014, Pages 760-769

  Nakamaru, Yoshinobu ^a   Hayashi, Yoshiharu ^a   Sekine, Mana ^a   Kinoshita, Shuji ^b   Thompson, Jeff ^c   Kawaguchi, Atsuhiro ^b   Davies, Martin ^c   Jürgen Heuer, Horst ^d   Yamazaki, Hiroshi ^e   Akimoto, Kei ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b Clinical Research Department Kissei Pharmaceutical   (Japan)

^c Mitsubishi Pharma Europe Ltd   (United Kingdom)

^d Nuvisan GmbH   (Germany)

^e SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

dipeptidyl peptidase 4 inhibitor; drug drug interactions; ketoconazole; pharmacokinetics; teneligliptin

Indexed keywords

DIGOXIN; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; TENELIGLIPTIN; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSPORT; DRUG WITHDRAWAL; FEMALE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN CELL; IN VITRO STUDY; LETHARGY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETICS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCYTOSIS; ADOLESCENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; GERMANY; MIDDLE AGED;

ADOLESCENT; ADULT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEALTHY VOLUNTEERS; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PYRAZOLES; THIAZOLIDINES;

EID: 84901478343     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.03.002     Document Type: Article

References (15)

1. B. Kreymann, G. Williams, and M.A. Ghatei et al. Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304
2. C.M. Edwards, J.F. Todd, and M. Mahmoudi et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39 Diabetes 48 1999 86 93
3. J. Buteau, S. Foisy, and C.J. Rhodes et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation Diabetes 50 2001 2237 2243
4. G. Xu, D.A. Stoffers, and J.F. Habener et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
5. A. Wettergren, B. Schjoldager, and P.E. Mortensen et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig Dis Sci 38 1993 665 673
6. A. Flint, A. Raben, and A. Astrup et al. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans J Clin Invest 101 1998 515 520
7. C.F. Deacon, M.A. Nauck, and M. Toft-Nielsen et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126 1131
8. J.J. Holst, and C.F. Deacon Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 1998 1663 1670
9. T. Eto, S. Inoue, and T. Kadowaki Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 14 2012 1040 1046
10. Y. Nakamaru, Y. Hayashi, and R. Ikegawa et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans Xenobiotica 44 2014 242 253
11. A.J. Scheen Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions Clin Pharmacokinet 49 2010 573 588
12. K. Yasuda, L.B. Lan, and D. Sanglard et al. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein J Pharmacol Exp Ther 303 2002 323 332
13. US Food and Drug Administration. Guidance for industry, drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations, draft guidance. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf. Accessed September 3, 2013.
14. D.J. Greenblatt, and L.L. von Moltke Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs J Clin Pharmacol 48 2008 1350 1355
15. M. Bebawy, and M. Chetty Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome Curr Drug Metab 10 2009 322 328